Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of COVID-19 and other coronaviruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The company is enrolling subjects in a Phase 1 trial with an antiviral candidate for pandemic and seasonal influenza A, and plans to initiate COVID-19 clinical trials in 2022 with an orally administered and inhalation/pulmonary delivered antiviral candidates.